Interv Akut Kardiol 2011; 10(5-6): 245-249

Contemporary and future treatment of thrombembolism in patients with atrial fibrillation

Petr Heinc, Ondřej Moravec, Jan Přeček, Jana Ondrušková, Miloš Táborský
I. interní klinika &ndash, kardiologická Fakultní nemocnice Olomouc

The last new European guidelines for the management of atrial fibrillation optimize antithrombotic treatment according to new risk

stratification (CHA2DS2Vasc score) but the future of alternative antithrombotic treatment using direct thrombin antagonists or factor

Xa inhibitors is negligibly mentioned. This article concerns the limitations and potential advantages of the new anticoagulant agents,

reviews the results of the trials with new anticoagulants in most advanced stages of clinical research and estimates perspectives of new

era of anticoagulant treatment.

Keywords: antithrombotic treatment, CHA2DS2Vasc score, future of direct thrombin antagonists, factor Xa inhibitors

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heinc P, Moravec O, Přeček J, Ondrušková J, Táborský M. Contemporary and future treatment of thrombembolism in patients with atrial fibrillation. Interv Akut Kardiol. 2011;10(5-6):245-249.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Guidelines for the management of atrial fibrillation: The Task Force for the Management of trial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 2010; 31(19): 2369-2429.
    2. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest. 2008; 133: 141S-159S. Go to original source...
    3. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133: 160S-198S. Go to original source...
    4. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133: 234S-256S. Go to original source...
    5. Testa L, Bhindi R, Agostoni P, et al. The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf. 2007; 6: 397-406. Go to original source... Go to PubMed...
    6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    7. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355: 2203-2216. Go to original source... Go to PubMed...
    8. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358: 2218-2230. Go to original source... Go to PubMed...
    9. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991; 324: 1865-1875. Go to original source... Go to PubMed...
    10. Viskov C, Just M, Laux V, et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009; 7: 1143-1151. Go to original source... Go to PubMed...
    11. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost. 2008; 6: 1697-1706. Go to original source... Go to PubMed...
    12. Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002; 419: 90-94. Go to original source... Go to PubMed...
    13. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990; 86: 385-391. Go to original source... Go to PubMed...
    14. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-552. Go to original source... Go to PubMed...
    15. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb Haemost. 2009; 101: 77-85. Go to original source... Go to PubMed...
    16. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Eng J Med. 2009; 361: 2342-2352. Go to original source... Go to PubMed...
    17. Patel MR, Mahaffey KW, Garg J, and the ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891. Go to original source... Go to PubMed...
    18. Granger CB, Alexander JH, et al. for the ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.